If you have not yet reconsented to the study for the most recent protocol update in 2021, this transfer reconsent process will also include an overview of these changes, which include:

• In-person visits, previously required at years 1, 4, and 10 post your implant date, have been removed
• New safety information regarding Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
• Compensation for Annual Questionnaire completion increased from $100 to $275
• New compensation of $100 for participants who complete their transfer by reconsenting to the study